What is it about?
Outline various proteins and pathway altered on relapse of HER2+ BC and combinations which can be used for the management of HER2+ BCBM.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Preparation of multi-targeted nano-carriers co-loaded with a chemotherapeutic drug and a natural anticancer drug can provide a synergistic effect for better management of HER2+ BCBM.
Perspectives
A combination of taxanes, TKI and PDK/AKT/mTOR inhibitors can be used for selective targeting while preparation of stimuli (pH/ROS/Enzyme/Light/Magnetic Field) responsive nanocarriers can be proven to be advantageous.
Mr. MANISH KUMAR
Indiana Institute Of Technology
Read the Original
This page is a summary of: A Mini-review on HER2 Positive Breast Cancer and its Metastasis: Resistance and Treatment Strategies, Current Nanomedicine, April 2020, Bentham Science Publishers,
DOI: 10.2174/2468187310666191223141038.
You can read the full text:
Contributors
The following have contributed to this page
